药物基因体学中的分子诊断市场－全球产业规模、份额、趋势、机会和预测（按产品、治疗领域、地区和竞争细分，2020-2030 年）

2024年，全球药物基因体学分子诊断市场规模达6.864亿美元，预计2030年将达到9.6932亿美元，复合年增长率为6.12%。受个人化医疗和精准医疗需求日益增长的推动，全球药物基因组学分子诊断市场正经历强劲增长。药物基因组学研究个别基因组成如何影响其对药物的反应，它高度依赖分子诊断技术来识别影响药物疗效和安全性的基因变异。

分子诊断在帮助医疗保健提供者根据个别患者定製药物治疗方案，从而最大程度地减少药物不良反应并优化治疗效果方面发挥关键作用。儘管前景光明，但该市场仍面临许多挑战，例如监管复杂性、资料隐私问题，以及需要加强临床验证和医疗专业人员的教育。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

测试成本高

主要市场趋势

关注儿科和老年人群

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球药物基因体学分子诊断市场的影响

第五章：全球药物基因体学分子诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品（试剂盒及检测试剂、试剂、服务、其他）
  • 依治疗领域（肿瘤学、神经系统疾病、心血管疾病、免疫系统疾病、传染病、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美药物基因体学分子诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲药物基因体学分子诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区药物基因体学分子诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲药物基因体学分子诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲药物基因组学分子诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球药物基因体学分子诊断市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Roche Diagnostics
• QIAGEN
• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• Abbott Molecular
• Genomind
• OneOme
• Myriad Genetics
• Invitae

第 17 章：策略建议

第18章调查会社について・免责事项

Global Molecular Diagnostics In Pharmacogenomics Market was valued at USD 686.40 Million in 2024 and is expected to reach USD 969.32 Million by 2030 with a CAGR of 6.12%. The global molecular diagnostics market in pharmacogenomics is experiencing robust growth, driven by the increasing demand for personalized medicine and precision healthcare. Pharmacogenomics, which studies how an individual's genetic makeup affects their response to drugs, relies heavily on molecular diagnostic technologies to identify genetic variations that influence drug efficacy and safety.

Molecular diagnostics play a critical role in enabling healthcare providers to tailor drug therapies to individual patients, thereby minimizing adverse drug reactions and optimizing therapeutic outcomes. Despite its promising outlook, the market faces challenges such as regulatory complexities, data privacy concerns, and the need for greater clinical validation and education among healthcare professionals.

Key Market Drivers

Growth in Healthcare Industry

The rapid growth of the healthcare industry is a pivotal driver fueling the expansion of the global molecular diagnostics in pharmacogenomics market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most significant and profitable segments are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which account for over USD 400 billion. As healthcare systems worldwide evolve to offer more personalized and effective treatments, there is an increasing demand for molecular diagnostic tools that enable tailored drug therapies based on an individual's genetic profile.

Hypertension and diabetes represent approximately 70% of all chronic disease cases. As India progresses through the third phase of the epidemiological transition characterized by degenerative, stress-related, and lifestyle-induced conditions the prevalence of chronic illnesses such as diabetes and cardiovascular diseases is rising significantly, driven in part by an ageing population. Rising prevalence of chronic and genetic disorders, coupled with the growing emphasis on precision medicine, is pushing healthcare providers and pharmaceutical companies to adopt pharmacogenomics-guided diagnostics. These diagnostics help optimize drug efficacy, minimize adverse drug reactions, and enhance overall patient outcomes, aligning with the healthcare industry's broader goals of improving quality of care and reducing costs.

Key Market Challenges

High Cost of Testing

The high cost of testing represents a significant challenge in the Global Molecular Diagnostics in Pharmacogenomics Market. Pharmacogenomic tests require sophisticated technology, specialized equipment, and skilled personnel, all of which contribute to substantial expenses. These elevated costs can limit the widespread adoption of pharmacogenomic testing, particularly in cost-sensitive healthcare systems and emerging markets.

Moreover, the financial burden associated with these tests often deters healthcare providers and patients from integrating pharmacogenomics into standard clinical practice. Although the promise of personalized medicine is compelling, the upfront investment needed for molecular diagnostics remains a critical barrier. Additionally, inconsistent reimbursement policies and limited insurance coverage across different regions exacerbate this challenge, leaving many patients to bear the cost out-of-pocket. This restricts access to pharmacogenomic testing and slows market growth.

Key Market Trends

Focus on Pediatric and Geriatric Populations

A significant emerging trend within the global molecular diagnostics in pharmacogenomics market is the growing focus on pediatric and geriatric populations. Currently, government policies on growth monitoring primarily target children under the age of five. Growth monitoring is a fundamental component of under-five clinics, where children are weighed regularly monthly during the first year, every two months in the second year, and quarterly thereafter up to the age of five to six years. These two demographic groups represent distinct patient segments with unique therapeutic needs and varying responses to medication, making personalized treatment approaches especially critical.

In pediatric care, molecular diagnostics enable precise identification of genetic factors that influence drug metabolism and efficacy in children. Given the physiological differences and developmental considerations in this population, pharmacogenomic testing helps clinicians optimize drug dosing and reduce the risk of adverse drug reactions, which are often more pronounced in younger patients.

Key Market Players

• Roche Diagnostics
• QIAGEN
• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• Abbott Molecular
• Genomind
• OneOme
• Myriad Genetics
• Invitae

Report Scope

In this report, the Global Molecular Diagnostics In Pharmacogenomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Diagnostics In Pharmacogenomics Market, By Product:

• Kits and Assays
• Reagents
• Services
• Others

Molecular Diagnostics In Pharmacogenomics Market, By Therapeutic Area:

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Molecular Diagnostics In Pharmacogenomics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Diagnostics In Pharmacogenomics Market.

Available Customizations:

Global Molecular Diagnostics In Pharmacogenomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Molecular Diagnostics in Pharmacogenomics Market

5. Global Molecular Diagnostics in Pharmacogenomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits and Assays, Reagents, Services, Others)
  • 5.2.2. By Therapeutic Area (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Molecular Diagnostics in Pharmacogenomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Mexico Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Canada Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Therapeutic Area

7. Europe Molecular Diagnostics in Pharmacogenomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. Germany Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Molecular Diagnostics in Pharmacogenomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. South Korea Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. Japan Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Therapeutic Area

9. South America Molecular Diagnostics in Pharmacogenomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. Argentina Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. Colombia Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Therapeutic Area

10. Middle East and Africa Molecular Diagnostics in Pharmacogenomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. UAE Molecular Diagnostics in Pharmacogenomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global Molecular Diagnostics in Pharmacogenomics Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Roche Diagnostics
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. QIAGEN
• 16.3. Thermo Fisher Scientific
• 16.4. Illumina, Inc.
• 16.5. Agilent Technologies
• 16.6. Abbott Molecular
• 16.7. Genomind
• 16.8. OneOme
• 16.9. Myriad Genetics
• 16.10. Invitae

17. Strategic Recommendations

18. About Us & Disclaimer